glp-1 and ibd Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review GLP-1 Receptor Agonists Reduce Colorectal
Description
Some patients report throat symptoms during treatment, though these may be coincidental rather than medication-related
Patients in the dataset had a 2.56 times higher rate of developing NAION within 1 year after starting a GLP-1 receptor agonist than those in the dataset who started a dipeptidyl peptidase-4 (DPP-4) inhibitor
10.1152/ajpendo.00665.2010 59
This means the highest supplement priority of all three medications
